Literature DB >> 10945497

Monoclonal antibody MA454 reveals a heterogeneous expression pattern of MAGE-1 antigen in formalin-fixed paraffin embedded lung tumours.

A A Jungbluth1, E Stockert, Y T Chen, D Kolb, K Iversen, K Coplan, B Williamson, N Altorki, K J Busam, L J Old.   

Abstract

Cancer/testis (CT) antigens such as those encoded by the MAGE-gene family are expressed in a wide variety of malignant neoplasms. In normal tissues, expression is generally restricted to testis. Current knowledge of the expression pattern of CT antigens is mainly based on mRNA analysis. Little is known about actual protein expression. We previously developed MA454, a monoclonal antibody (mAb) to MAGE-1 recombinant protein. By employing antigen retrieval techniques, we show that MA454 is reactive on formalin-fixed paraffin-embedded tissues. Immunohistochemical (IHC) analysis of a normal tissue panel revealed staining solely in germ cells of testes. A series of 59 lung tumours was co-typed for MAGE-1 expression by RT-PCR and by immunohistochemistry with MA454. MA454 was positive in 19/59 cases (32%). MAGE-1 mRNA was found in 17 of the 54 cases (32%) available for RT-PCR. Of the 19 MA454-reactive tumours, 15 showed a highly heterogeneous pattern of expression. The other 4 MA454 positive cases revealed immunoreactivity in >25% of tumour areas. Of the 53 cases typed for both, mRNA and protein expression, 48 co-typed whereas 5 cases were discrepant, a likely consequence of heterogeneous MAGE-1 expression. The predominantly focal expression of MAGE-1 suggests that this antigen might not be sufficient as a sole target for immunotherapeutic approaches.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10945497      PMCID: PMC2374655          DOI: 10.1054/bjoc.2000.1291

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  30 in total

1.  MAGE-11 protein is highly conserved in higher organisms and located predominantly in the nucleus.

Authors:  M Jurk; E Kremmer; U Schwarz; R Förster; E L Winnacker
Journal:  Int J Cancer       Date:  1998-03-02       Impact factor: 7.396

2.  MAGE-1 and MAGE-3 tumor rejection antigens in human germ cell tumors.

Authors:  J C Cheville; P C Roche
Journal:  Mod Pathol       Date:  1999-10       Impact factor: 7.842

Review 3.  T cell defined tumor antigens.

Authors:  B J Van den Eynde; P van der Bruggen
Journal:  Curr Opin Immunol       Date:  1997-10       Impact factor: 7.486

4.  cDNA and protein characterization of human MAGE-10.

Authors:  D Rimoldi; S Salvi; D Reed; P Coulie; V C Jongeneel; E De Plaen; F Brasseur; A M Rodriguez; T Boon; J C Cerottini
Journal:  Int J Cancer       Date:  1999-09-09       Impact factor: 7.396

5.  MAGE-3 immunoreactivity in formalin-fixed, paraffin-embedded primary and metastatic melanoma: frequency and distribution.

Authors:  G F Hofbauer; C Schaefer; C Noppen; R Böni; J Kamarashev; F O Nestle; G C Spagnoli; R Dummer
Journal:  Am J Pathol       Date:  1997-12       Impact factor: 4.307

6.  The tumour-associated antigen MAGE-1 is detectable in formalin-fixed paraffin sections of malignant melanoma.

Authors:  F Gudat; M Zuber; U Dürmüller; T Kocher; C Schaefer; C Noppen; G Spagnoli
Journal:  Virchows Arch       Date:  1996-10       Impact factor: 4.064

7.  A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma.

Authors:  P van der Bruggen; C Traversari; P Chomez; C Lurquin; E De Plaen; B Van den Eynde; A Knuth; T Boon
Journal:  Science       Date:  1991-12-13       Impact factor: 47.728

8.  Identification of the MAGE-1 gene product by monoclonal and polyclonal antibodies.

Authors:  Y T Chen; E Stockert; Y Chen; P Garin-Chesa; W J Rettig; P van der Bruggen; T Boon; L J Old
Journal:  Proc Natl Acad Sci U S A       Date:  1994-02-01       Impact factor: 11.205

Review 9.  Human tumor rejection antigens MAGE.

Authors:  K Itoh; A Hayashi; M Nakao; T Hoshino; N Seki; S Shichijo
Journal:  J Biochem       Date:  1996-03       Impact factor: 3.387

10.  MAGE-1 gene product is a cytoplasmic protein.

Authors:  E Schultz-Thater; A Juretic; P Dellabona; U Lüscher; W Siegrist; F Harder; M Heberer; M Zuber; G C Spagnoli
Journal:  Int J Cancer       Date:  1994-11-01       Impact factor: 7.396

View more
  35 in total

1.  Epigenetic modulation of MAGE-A3 antigen expression in multiple myeloma following treatment with the demethylation agent 5-azacitidine and the histone deacetlyase inhibitor MGCD0103.

Authors:  Amberly Moreno-Bost; Susann Szmania; Katie Stone; Tarun Garg; Antje Hoerring; Jackie Szymonifka; John Shaughnessy; Bart Barlogie; H Grant Prentice; Frits van Rhee
Journal:  Cytotherapy       Date:  2010-12-20       Impact factor: 5.414

2.  A panel of cancer-testis genes exhibiting broad-spectrum expression in haematological malignancies.

Authors:  Amanda P Liggins; Seah H Lim; Elizabeth J Soilleux; Karen Pulford; Alison H Banham
Journal:  Cancer Immun       Date:  2010-08-23

Review 3.  [Expression of cancer testis (CT) antigens in pediatric and adolescent melanomas].

Authors:  N Behrendt; T Schultewolter; K Busam; D Frosina; G Spagnoli; A Jungbluth
Journal:  Pathologe       Date:  2017-07       Impact factor: 1.011

Review 4.  Cancer/testis (CT) antigens, carcinogenesis and spermatogenesis.

Authors:  Yan-Ho Cheng; Elissa Wp Wong; C Yan Cheng
Journal:  Spermatogenesis       Date:  2011-07-01

5.  Expression of cancer-testis (CT) antigens in placenta.

Authors:  Achim A Jungbluth; Wilson A Silva; Kristin Iversen; Denise Frosina; Bushra Zaidi; Keren Coplan; Susannah K Eastlake-Wade; Sandra B Castelli; Giulio C Spagnoli; Lloyd J Old; Martin Vogel
Journal:  Cancer Immun       Date:  2007-08-24

6.  Cancer/testis (CT) antigens are expressed in fetal ovary.

Authors:  Peter T Nelson; Paul J Zhang; Giulio C Spagnoli; John E Tomaszewski; Theresa L Pasha; Denise Frosina; Otavia L Caballero; Andrew J G Simpson; Lloyd J Old; Achim A Jungbluth
Journal:  Cancer Immun       Date:  2007-01-12

7.  Cancer-testis antigens: the current status on antigen regulation and potential clinical use.

Authors:  Seah H Lim; Yana Zhang; Jian Zhang
Journal:  Am J Blood Res       Date:  2012-01-01

8.  EWSR1-FLI1 Activation of the Cancer/Testis Antigen FATE1 Promotes Ewing Sarcoma Survival.

Authors:  Zachary R Gallegos; Patrick Taus; Zane A Gibbs; Kathleen McGlynn; Nicholas C Gomez; Ian Davis; Angelique W Whitehurst
Journal:  Mol Cell Biol       Date:  2019-06-27       Impact factor: 4.272

9.  Tumor-associated antigen profiling in breast and ovarian cancer: mRNA, protein or T cell recognition?

Authors:  Simone Kayser; Iris Watermann; Christine Rentzsch; Toni Weinschenk; Diethelm Wallwiener; Brigitte Gückel
Journal:  J Cancer Res Clin Oncol       Date:  2003-06-26       Impact factor: 4.553

10.  MAGE-A1 interacts with adaptor SKIP and the deacetylase HDAC1 to repress transcription.

Authors:  Sandra Laduron; Rachel Deplus; Sifang Zhou; Olga Kholmanskikh; Danièle Godelaine; Charles De Smet; S Diane Hayward; François Fuks; Thierry Boon; Etienne De Plaen
Journal:  Nucleic Acids Res       Date:  2004-08-17       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.